Despite recent improvements in imaging and therapy, prostate cancer (PCa) still causes
substantial morbidity and mortality. In surgical treatment, incomplete resection of PCa and …

Oligometastatic prostate cancer (OMPC), generally defined by presence of five or fewer
metastatic sites on imaging, represents a transitional state between localized and …

Summary N-acetyl-aspartyl-glutamate (NAAG) is a peptide-based neurotransmitter that has
been extensively studied in many neurological diseases. In this study, we show a specific …

Background: Mipsagargin (G-202) is a thapsigargin-based prodrug with cytotoxic activity
masked by a peptide that is cleaved by prostate-specific membrane antigen (PSMA), a …

Abstract Purpose of Review To critically review the potential clinical applications of prostate-
specific membrane antigen (PSMA) radioactive ligands in renal cell carcinoma (RCC) …

Background Triple-negative breast cancer has extremely high risk of relapse due to the lack
of targeted therapies, intra-and inter-tumoral heterogeneity, and the inherent and acquired …

Abstract Context Advanced prostate cancer (PCa) is a prominent cause of cancer death in
men; positron emission tomography (PET) imaging may play a relevant role in detecting …

Prostate specific membrane antigen (PSMA) is a marker for diagnosis and targeted delivery
of therapeutics to advanced/metastasized prostate cancer. We report a liposome-based …

Prostate cancer is primarily fatal after it becomes metastatic and castration-resistant despite
novel combined hormonal and chemotherapeutic regimens. Hence, new therapeutic …

Prostate cancer (PCa) is the most common male urogenital malignancy worldwide. Surgery,
endocrine therapy, radiotherapy, and chemotherapy are the main clinical management …